ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

January 25, 2008 09:15 ET

ALDA's T36® Successfully Completes First Clinical Tests

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 25, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has received results from clinical tests of its T36® formulation ("T36®") for use as a skin antiseptic, a hygienic hand rub, a pre-surgical hand wash and a pre-injection scrub. In these clinical studies, T36® demonstrated complete efficacy after only 30 seconds of exposure to all 6 species of bacteria tested, including VRE (Vancomycin-Resistant Enterococcus), MRSA (Methicillin-Resistant Staphylococcus aureus) and MDR (Multi-Drug Resistant) Enterococcus faecium. These three species of bacteria are critical concerns in hospitals, nursing homes and other medical facilities based on their resistance to many antibiotics and other treatments. The clinical testing was completed according to the standards required by the FDA in the US, Health Canada and the European Medicines Agency, which included exposure of the bacteria to T36® for periods ranging from 30 seconds to 30 minutes.

Dr. Terrance Owen, President & CEO, states, "We were confident that T36® would do well in these tests given the extensive studies that ALDA has already done using 3-minute exposure times and the successful 1-minute test against MRSA that we announced on December 6, 2007. However, we needed to conduct new tests to meet the specific requirements of the regulatory agencies in Canada, Europe and the US. We are very pleased that T36® performed extremely well in these tests. With this data, we can now start planning human trials for Canada and the EU, as well as preparing for our pre-IND (Investigational New Drug) meeting with the FDA. After that meeting, we will know precisely what further testing is required before starting human trials for submission to the FDA."

About Bioscience Laboratories, Inc.

BioScience Laboratories, Inc. located in Montana, has been providing antimicrobial product testing and result interpretation for various industries, including healthcare, pharmaceutical, personal care and consumer products for over 16 years.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    or
    ALDA Pharmaceuticals Corp.
    Peter Chen
    Distribution & Sales Contact
    (604) 521-8300 Ext. 3
    (604) 521-8322 (FAX)
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com